Gilead Forecasts 6% HIV Sales Growth and $800M Yeztugo Target in 2026
Gilead Sciences forecasts 6% growth in its HIV franchise for 2026, driven by continued uptake of its antiretroviral therapies. The company aims for Yeztugo to generate $800 million in sales, bolstering its revenue mix and offsetting potential declines in older portfolio assets.
1. 2026 HIV Franchise Growth Outlook
Gilead projects its HIV portfolio will grow by 6% next year, supported by sustained patient demand for its single-tablet regimens and new prescription starts. The forecast reflects management's confidence in maintaining market share as treatment guidelines evolve.
2. Yeztugo Revenue Potential
Yeztugo, Gilead's late-stage antiviral therapy, is targeted to achieve $800 million in 2026 sales. The company expects Yeztugo's competitive profile, including dosing convenience and patent exclusivity, to drive uptake.